Summary

Overview
Global brachytherapy devices market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Brachytherapy is a approach utilized for the treatment of specific kinds of cancer and additional conditions. It implicates positioning seeds, ribbons, or capsules that include a radiation source inside the body in or near the tumor. This is occasionally anointed as internal radiation therapy.
Market Dynamics: Drivers & Restraints
Increasing Cases of Cancer
The increasing cases of cancer are expected to boost the global market growth during the forecast period. For instance, according to data from Breastcancer.org, in March 2022, an estimated 287,850 new cases of invasive breast cancer were anticipated to be interpreted in females in the U.S., along with 51,400 fresh cases of non-invasive (in situ) breast cancer in 2022. Moreover, according to the International Agency for Research on Cancer (IARC) 2020 report, in 2020, about 2.3 million new cases of breast cancer were interpreted globally, over any other form of cancer, and by 2040, the incidence of breast cancer is projected to reach about 3 million cases and therefore, with the growing load of breast cancer expected to boost brachytherapy market over the forecast period.
Additionally, the growing geriatric population and increased research activities are among the additional factors boosting the global market during the forecast period.
Lack of Skilled Professionals
However, the shortage of skilled professionals to conduct radiotherapy is expected to hamper the market growth over the forecast period. Further, the lack of awareness and high cost are among the additional factors slowing the global market growth during the forecast period.
Segment Analysis
The global brachytherapy devices market is segmented based on product, dosage type, indication, end user and region.
Seeds Product Type Segment is Expected to Dominate Market
Owing to the increasing market developments in the seeds product type segment it is estimated to dominate the global market during the forecast period. For instance, in February 2023, Isoray, Inc., a medical technology corporation and developer in seed brachytherapy, merged with privately held Viewpoint Molecular Targeting, Inc. The integrated corporations’ focus is expected to be the refinement of cancer therapies utilizing radiation, radiopharmaceuticals, and imaging technologies so that accurate, targeted medical doses are administered straight to cancer patient tumor sites. Moreover, in January 2021, Isoray Medical, Inc., obtained U.S. Food and Drug Administration (FDA) 510(k) authorization for the usage of C4 Imaging’s Sirius positive-signal MRI (Magnetic Resonance Imaging) Markers with Isoray’s Cesium-131, brachytherapy seeds. Further, in June 2020, the FDA cleared (510 K authorized) and CE marked cesium-131 permanent brachytherapy seeds for Prostate cancer, Brain tumors, Head and neck, Gynecological tumors, Lung, etc.
Geographical Analysis
North America is Expected to Dominate the Global Market
Owing to the increased cancer cases and market developments in North America are expected to boost the regional market growth dominating the global market during the forecast period. For instance, according to the American Cancer Society in January 2023, breast cancer was the most common cancer in females in the United States. It accounts for 30% (or 1 in 3) of all recent female cancers in the nation annually. Also, according to the same reference, about 297,790 fresh cases of invasive breast cancer and 55,720 new cases of ductal carcinoma in situ (DCIS) are estimated to be diagnosed in females by the end of 2023. Further, in July 2021, GenesisCare, a top multinational provider of integrated cancer care, completed the order of 27 Flexitron brachytherapy afterloader systems, including assistance contracts. The cancer treatment devices intend to allow GenesisCare to persist to support in the latest world-class technology while delivering access to high-quality care to their patients throughout their U.S. centers.
COVID-19 Impact Analysis
The COVID-19 pandemic had a negative impact on the global market. The lockdown imposed in various countries led to reduced rates of radiotherapy, thereby affecting the revenue generated by the market. A population-based study was carried out in England to analyze the impact of cancer on radiotherapy during the pandemic. The study revealed a significant drop in mean weekly radiotherapy courses in April, May, and June 2020 compared to the corresponding months in 2019. However, with the easing of lockdown restrictions, the radiotherapy market is expected to recover gradually in the coming years.
Market Segmentation
By Product
• Seeds
• Applicators & Afterloaders
• Brachytherapy Systems
• Others
By Dosage Type
• High-Dose Rate (HDR) Brachytherapy
• Low-Dose Rate (LDR) Brachytherapy
By Indication
• Prostate Cancer
• Gynecological Cancer
• Breast Cancer
• Head and Neck Cancer
• Others
By End User
• Hospitals
• Specialty Clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In September 2021, Unicancer acquired multiple Radixact Systems of Accuray, Inc. with the ClearRT with a purpose to deliver personalized therapy to patients in Europe.
• In August 2021, iCAD, Inc.’s Xoft Axxent Electronic Brachytherapy System for the treatment of recurrent glioblastoma demonstrated substantial progress in the general survival of patients who obtained this treatment.
• In Jun-2020, FDA authorized (510 K approved) and CE marked cesium-131 permanent brachytherapy seeds for Prostate cancer, Brain tumors, Head & Neck, Gynecological tumors, Lung etc.
Competitive Landscape
The major global players in the market include Varian Medical Systems, Inc., Becton, Dickinson & Company, Elekta AB, Isoray Medical, Inc., Eckert & Ziegler BEBIG, ICAD, Inc., CIVCO Medical Solutions, Theragenics Corporation, Carl Zeiss Meditec AG and Argon Medical.
Why Purchase the Report?
• To visualize the global brachytherapy devices market segmentation based on product, dosage type, indication, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of brachytherapy devices market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key product of all the major players.
The global brachytherapy devices market report would provide approximately 69 tables, 69 figures and 182 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product
3.2. Snippet by Dosage Type
3.3. Snippet by Indication
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Cases of Cancer
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Lack of Skilled Professionals
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Pricing Analysis
5.3. Regulatory Analysis
5.4. Patent Analysis
5.5. Technology Trend
5.6. Unmet Need
5.7. End-user Trend
5.8. SWOT Analysis
5.9. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
7.1.2. Market Attractiveness Index, By Product
7.2. Seeds*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Applicators & Afterloaders
7.4. Brachytherapy Systems
7.5. Others
8. By Dosage Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
8.1.2. Market Attractiveness Index, By Dosage Type
8.2. High-Dose Rate (HDR) Brachytherapy*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Low-Dose Rate (LDR) Brachytherapy
9. By Indication
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.1.2. Market Attractiveness Index, By Indication
9.2. Prostate Cancer*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Gynecological Cancer
9.4. Breast Cancer
9.5. Head and Neck Cancer
9.6. Others
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Varian Medical Systems, Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Becton, Dickinson & Company
13.3. Elekta AB, Inc.
13.4. ISORAY MEDICAL, INC.
13.5. Eckert & Ziegler BEBIG
13.6. ICAD, Inc.
13.7. CIVCO Medical Solutions
13.8. Theragenics Corporation
13.9. Carl Zeiss Meditec AG
13.10. Argon Medical.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us